WW45 Transgenic Mouse Model for Tumor Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The Hippo signaling pathway, crucial for regulating cell proliferation and differentiation in mammals, is not fully understood, particularly in mammals, where mutations lead to tumorigenesis, and existing methods fail to effectively regulate differentiation and cell-cycle exit in epithelial tissues.
Innovation Solution
Regulating the expression and phosphorylation of the WW45 protein and Yes-associated protein (YAP) to control cell differentiation, using transgenic organisms with deleted WW45 genes to induce tumors, and screening for anti-tumor agents by measuring WW45 protein expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If transgenic mice with deleted WW45 genes are used to study Hippo pathway function, then insights into cell proliferation and differentiation mechanisms are gained, but the complexity of generating and maintaining transgenic models increases
Solution Approach 1:
The patent uses transgenic mice as intermediary models to study the Hippo pathway function. By deleting WW45 genes in mice, researchers can observe the downstream effects on cell proliferation and differentiation without directly manipulating human cells, thus gaining insights into pathway mechanisms while using a manageable animal model system
Solution Approach 2:
The patent creates transgenic mouse models that copy the genetic deletion scenario to study Hippo pathway function. By generating mice with deleted WW45 genes, researchers replicate the molecular conditions needed to observe pathway effects in a living system, allowing indirect study of human-relevant mechanisms through a simplified animal model
2Reliability
If WW45 expression is regulated to control cell differentiation, then terminal differentiation and cell-cycle exit are improved, but the precision of controlling differentiation timing and location becomes more challenging
Solution Approach 1:
The patent employs Cre-LoxP recombination system to achieve local deletion of WW45 genes in specific tissues such as intestine and skin. This allows differentiation control to be applied locally rather than systemically, enabling precise spatial control of where differentiation occurs while maintaining reliability of the differentiation process in targeted areas
Solution Approach 2:
The patent uses conditional knockout strategies where WW45 deletion is triggered at specific developmental stages or in response to specific signals. This preliminary action allows researchers to control exactly when differentiation should occur by timing the gene deletion event, thereby achieving precise temporal control over the differentiation process
3Reliability
If transgenic mice are used for screening anti-tumor compounds, then tumor models are established, but the time required for compound screening and validation increases
Solution Approach 1:
The patent uses partial deletion of WW45 genes or conditional knockout in specific tissues rather than complete systemic deletion. This partial action creates tumor models that are sufficiently pathological for screening purposes but develop at accelerated rates compared to more severe models, thereby reducing the time required for tumor formation and compound testing while maintaining model validity
Solution Approach 2:
The patent employs inducible systems where WW45 deletion can be triggered at different time points and with different intensities. By changing the parameters of gene deletion (timing, extent, tissue specificity), researchers can optimize tumor model development speed to match screening timelines while preserving the biological relevance needed for reliable compound validation
Data Source
AI summary
Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms with loss of expression of the differentiation regulator, and methods of preparing the transgenic organisms, are provided.